Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

Abstract: In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the group consisting of copper iodide, copper chloride, copper bromide, copper sulfate, copper formate, or combinations thereof.

Abstract: Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Abstract: A coating device for coating a medical device with a drug-eluting material uses an in-process drying station between coats to improve a drug release profile. The drying station includes a heat nozzle configured for applying a uniform drying gas.

Abstract: A method and coating for reducing the release rate of an active agent from an implantable device, such as a stent, is disclosed.

Abstract: Method and systems for manufacturing a tablet comprising an electronic device are disclosed. In one method, a powdered material is provided into a die cavity of a tablet press and an electronic device is dispensed from a tape-and-reel carrier tape operatively coupled to the tablet press into the die cavity. The powdered material and the electronic device are compressing to form a tablet. A system comprises a tablet press comprising a die cavity for receiving a powdered material and an electronic device therein, an upper punch, and a lower punch. The upper and lower punches are operative to form the powdered material and the electronic device into a tablet. A tape-and-reel carrier tape is operatively coupled to the tablet press, where the carrier tape is configured for holding the electronic device. A transfer mechanism is used to transfer the electronic device from the tape carrier to the die cavity.

Abstract: Method and systems for manufacturing a tablet comprising an electronic device are disclosed. In one method, a powdered material is provided into a die cavity of a tablet press and an electronic device is dispensed from a tape-and-reel carrier tape operatively coupled to the tablet press into the die cavity. The powdered material and the electronic device are compressing to form a tablet. A system comprises a tablet press comprising a die cavity for receiving a powdered material and an electronic device therein, an upper punch, and a lower punch. The upper and lower punches are operative to form the powdered material and the electronic device into a tablet. A tape-and-reel carrier tape is operatively coupled to the tablet press, where the carrier tape is configured for holding the electronic device. A transfer mechanism is used to transfer the electronic device from the tape carrier to the die cavity.

Abstract: A method of coating a stent is presented such that less than 50% of the total amount of 40-O-(2-hydroxyl)ethyl-rapamycin, or an analog or derivative thereof, is released in vivo in a 24 hour period, wherein the method comprises exposing the coating to sufficient temperature to modify the structure of the polymer.

Abstract: A coating device for coating a medical device with a drug-eluting material uses an in-process drying station between coats to improve a drug release profile. The drying station includes a heat nozzle configured for applying a uniform drying gas.

Abstract: A coating device for coating a medical device with a drug-eluting material uses an in-process drying station between coats to improve a drug release profile. The drying station includes a heat nozzle configured for applying a uniform drying gas.

Abstract: A method and coating for reducing the release rate of an active agent from an implantable device, such as a stent, is disclosed.

Abstract: A coating and a method of coating an implantable medical device, such as a stent, is disclosed. The method includes subjecting the coating to a thermal condition such as a temperature above the glass transition temperature of a polymer included in the coating.